April 1, 1998Investigative Radiology

Assessment of Myocardial Perfusion by Intermittent Harmonic Power Doppler Using SonoVue, a New Ultrasound Contrast Agent

View Full Paper

Ask AI

Bookmark

Population

In vitro tissue-mimicking phantom and in vivo minipigs

Comparison

SonoVue administered intravenously with… vs Different pulse repetition frequencies and…

Design

Preclinical

Authors

ABAnne BroilletBracco (Switzerland)JPJérôme PuginierBracco (Switzerland)RVROGER VENTRONEBracco (Switzerland)

Discussion

Member takes

Implication

Supports preclinical use of SonoVue for detecting myocardial perfusion differences; leaves open human translation and clinical validation.

Structured PICO

Population

In vitro tissue-mimicking phantom and in vivo minipigs (closed-chest and open-chest with reversible left anterior descending coronary artery occlusion)

Intervention

SonoVue (ultrasound contrast agent) administered intravenously (bolus 0.01-0.05 mL/kg or infusion 0.1 mL/kg/minute) with intermittent harmonic power Doppler (IHPD) imaging at varying pulse repetition frequencies (PRFs 500 to 6000 Hz)

Comparator

Different pulse repetition frequencies (PRFs) and healthy vs. ischemic myocardial beds

Outcome

Efficacy of SonoVue for myocardial opacification and detection of perfusion differences, evaluated qualitatively using a subjective scoring system and quantitatively using a digital image analyzersurrogate

SonoVue is a promising ultrasound contrast agent for detecting myocardial perfusion abnormalities and blood flow differences using intermittent harmonic power Doppler imaging.

Cite This Study

Broillet et al. (1998) studied this question.

synapsesocial.com/papers/6a87372ce0e6abca40d3cc27 https://doi.org/10.1097/00004424-199804000-00003

View Full Paper

Ask AI

Bookmark

Implication

Supports preclinical use of SonoVue for detecting myocardial perfusion differences; leaves open human translation and clinical validation.